Congruence Therapeutics

Congruence Therapeutics is a Montreal-based biotechnology company founded in 2021 by Clarissa Desjardins, PhD, and Michael Rock Goldsmith.

The company specializes in computational and experimental drug discovery, focusing on designing small-molecule pharmacological stabilizers for diseases caused by protein misfolding. Congruence Therapeutics aims to address rare diseases and severe genetic conditions that currently lack effective treatments. The company utilizes advanced techniques in protein dynamics, biophysics, machine learning, and computational chemistry through its in silico platform. This platform enables the rapid design of validated small molecules, bridging computational modeling with experimental validation. Congruence's flagship innovation, the RevenirTM Product Engine, captures biophysical features of proteins and identifies novel pockets for drug targeting, facilitating the development of therapies for previously untreatable conditions. With approximately $139.5 million in funding and a growing workforce, Congruence Therapeutics is positioned for continued growth in the drug discovery sector.